Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner

Vaccine

Volumn 30, Issue 36, 2012, Pages 5368-5372

  Taguchi, Ayumi ^a   Kawana, Kei ^a   Yokoyama, Terufumi ^b   Adachi, Katsuyuki ^a   Yamashita, Aki ^a   Tomio, Kensuke ^a   Kojima, Satoko ^a   Oda, Katsutoshi ^a   Fujii, Tomoyuki ^a   Kozuma, Shiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Okinawa Industry Support Center   (Japan)

Author keywords

HPV therapeutic vaccine; Japanese herbal medicines; Lactobacillus based vaccine; Mucosal immune response; Oral immunization

Indexed keywords

BU ZHONG YI QI TANG; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LABILE ENTEROTOXIN T SUBUNIT; LACE7 PROTEIN; PROTEIN E7; SHI QUAN DA BU TANG; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADD ON THERAPY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOMODULATION; INTESTINE MUCOSA; LACTOBACILLUS CASEI; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; CYTOKINES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; IMMUNITY, MUCOSAL; LACTOBACILLUS CASEI; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES;

EID: 84864010450     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.027     Document Type: Article

References (37)

1. Ferlay J., Bray F., Pisani P. Cancer incidence, mortality and prevalence worldwide. IARC Cancer base no. 5, version 2.0 2004, IARC Press, Lyon.
2. Ressler S., Scheiden R., Dreier K., Laich A., Müller-Holzner E., Pircher H., et al. High-risk Human Papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007, 13(23):7067-7072.
3. Trimble C.L., Frazer I.H. Development of therapeutic HPV vaccines. Lancet Oncol 2009, 10(10):975-980.
4. Poo H., Pyo H.M., Lee T.Y., Yoon S.W., Lee J.S., Kim C.J., et al. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. Int J Cancer 2006, 119(7):1702-1709.
5. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 19(27):3652-3660.
6. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23(9):2242-2249.
7. Kaufmann A.M., Nieland J.D., Jochmus I., Baur S., Friese K., Gabelsberger J., et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007, 121(12):2794-2800.
8. Fiander A.N., Tristram A.J., Davidson E.J., Tomlinson A.E., Man S., Baldwin P.J., et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006, 16(3):1075-1081.
9. Roman L.D., Wilczynski S., Muderspach L.I., Burnett A.F., O'Meara A., Brinkman J.A., et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007, 106(3):558-566.
10. García-Hernández E., González-Sánchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzmán C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006, 13(6):592-597.
11. Garcia F., Petry K.U., Muderspach L., Gold M.A., Braly P., Crum C.P., et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004, 103(2):317-326.
12. Kunisawa J., Kurashima Y., Kiyono H. Gut-associated lymphoid tissues for the development of oral vaccines. Adv Drug Deliv Rev 2011, 30.
13. Martinelli E., Tharinger H., Frank I., Arthos J., Piatak M., Lifson J.D., et al. HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog 2011, 7(6):e1002109.
14. Csencsits K.L., Jutila M.A., Pascual D.W. Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site. J Immunol 1999, 163(3):1382-1389.
15. Hänninen A., Taylor C., Streeter P.R., Stark L.S., Sarte J.M., Shizuru J.A., et al. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest 1993, 92(5):2509-2515.
16. Kelly K.A., Rank R.G. Identification of homing receptors that mediate the recruitment of CD4T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 1997, 65(12):5198-5208.
17. Mantis N.J., Wagner J. Analysis of adhesion molecules involved in leukocyte homing into the basolateral pockets of mouse Peyer's patch M cells. J Drug Target 2004, 12(2):79-87.
18. Adachi K., Kawana K., Yokoyama T., Fujii T., Tomio A., Miura S., et al. Oral immunization with Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocyte against HPV16 E7. Vaccine 2010, 28:2810-2817.
19. Hawkins R.A., Rank R.G., Kelly K.A. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. Infect Immun 2000, 68(10):5587-5594.
20. Kiyohara H., Nagai T., Munakata K., Nonaka K., Hanawa T., Kim S.J., et al. Stimulating effect of Japanese herbal (kampo) medicine, hochuekkito on upper respiratory mucosal immune system. Evid Based Complement Alternat Med 2006, 3(4):459-467.
21. Zhao X., Fan Y., Wang D., Hu Y., Guo L., Ruan S., et al. Immunological adjuvant efficacy of glycyrrhetinic acid liposome against Newcastle disease vaccine. Vaccine 2011, 29(52):9611-9617.
22. Ma X., Guo Z., Shen Z., Wang J., Hu Y., Wang D. The immune enhancement of propolis adjuvant on inactivated porcine parvovirus vaccine in guinea pig. Cell Immunol 2011, 270(1):13-18.
23. Underwood J.R., Chivers M., Dang T.T., Licciardi P.V. Stimulation of tetanus toxoid-specific immune responses by a traditional Chinese herbal medicine. Vaccine 2009, 27(47):6634-6641.
24. Saiki I. A Kampo medicine "Juzen-taiho-to" - prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull 2000, 23(6):677-688.
25. Tsuchiya M., Kono H., Matsuda M., Fujii H., Rusyn I. Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer 2008, 123(11):2503-2511.
26. Cho J.M., Sato N., Kikuchi K. Prophylactic antitumor effect of Hochu-ekki-to (TJ-41) by enhancing natural killer cell activity. In Vivo 1991, 5:389-392.
27. Kataoka T., Akagawa K.S., Tokunaga T., Nagao S. Activation of macrophages with Hochu-ekki-to. Jpn J Cancer Chemother 1989, 16:1490-1493.
28. Takagi Y., Azuma N., Kawai S., Maeda A. Antibody response of Kampo-hozai after influenza B immunization in old mice. Jpn Soc Vaccinol 2002, 6:72.
29. Matsumoto T., Noguchi M., Hayashi O., Makino K., Yamada H. Hochuekkito, a Kampo (traditional Japanese herbal) Medicine enhances mucosal IgA antibody response in mice immunized with antigen-entrapped biodegradable microparticles. Evid Based Complement Alternat Med 2010, 7(1):69-77.
30. Vintiñi E.O., Medina M.S. Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei. BMC Immunology 2011, 12:46-59.
31. Davidson E.J., Boswell C.M., Sehr P., Pawlita M., Tomlinson A.E., McVey R.J., et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003, 63:6032-6041.
32. Fiander A.N., Tristram A.J., Davidson E.J., Tomlinson A.E., Man S., Baldwin P.J., et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006, 16:1075-1081.
33. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
34. Kojima S., Kawana K., Fujii T., Yokoyama T., Miura S., Tomio K., et al. Characterization of intraepithelial lymphocytes (IELs) residing in the cervical mucosa of patients with human papillomavirus (HPV)-infected intraepithelial neoplastic lesions. Am J Reprod Immunol 2011, 66:435-443.
35. Kajikawa A., Satoh E., Leer R.J., Yamamoto S., Igimi S. Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis. Vaccine 2007, 25(18):3599-3605.
36. Mohamadzadeh M., Olson S., Kalina W.V., Ruthel G., Demmin G.L., Warfield K.L., et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci USA 2005, 102(8):2880-2885.
37. Koizumi S., Wakita D., Sato T., Mitamura R., Izumo T., Shibata H., et al. Essential role of Toll-like receptors for dendritic cell and NK1.1(+) cell-dependent activation of type 1 immunity by Lactobacillus pentosus strain S-PT84. Immunol Lett 2008, 120(1-2):14-19.